Dr Matthew Ware completed his Bachelor's and Master's degrees at Swansea before enrolling on its collaborative PhD with Houston Methodist Research Institute in Texas - one of the initiatives to come out of the Texas Strategic Partnership.

After graduating, Dr Ware remained in Texas, researching new treatments for pancreatic and hepatic cancers at Baylor College of Medicine. His research resulted in two patents, including the CorleyWare Device - a new intra-operative device to treat portions of cancer that cannot be removed by a surgeon’s scalpel.

In summer 2018, Dr Ware took up a new role as a scientist for Celgene, a biotechnology company that discovers, develops and commercializes medicines for cancer and inflammatory disorders. Since November 2019, Dr Ware has worked at Bristol Myers-Squibb as a scientist, to deliver better medicines for patients with cancer.